Enhanced expression of miR-126 could increase the sensitivity of NSCLC cells to anticancer agents through negative regulation of a VEGF/PI3K/Akt/MRP1 signaling pathway [37]. This evidence concerns the gene AKT1 and non-small cell lung carcinoma.